Correspondence 0001193125-24-136153 from Silence Therapeutics plc (SLN, SLNCF) (CIK 0001479615) (SLN)
Silence Therapeutics plc (SLN, SLNCF) (CIK 0001479615)
Date: May 10, 2024 · CIK: 0001479615 · Accession: 0001193125-24-136153
AI Filing Summary & Sentiment
File numbers found in text: 333-279185
Letter
Re: Silence Therapeutics plc (the “Company”)
May 10, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jimmy McNamara
Registration Statement on Form F-3
Filed: May 7, 2024
File No. 333-279185
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:00 p.m. Eastern Time on May 14, 2024, or as soon thereafter as is practicable, or at such later time as the Company may orally request via telephone call to the staff. The Company hereby authorizes each of Courtney T. Thorne and Eric Blanchard of Cooley LLP to make such request on its behalf.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Courtney T. Thorne of Cooley LLP at (617) 937-2318, or in her absence, Eric Blanchard of Cooley LLP at (617) 937-2445.
Very truly yours,
Silence Therapeutics plc
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 10, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara Re: Silence Therapeutics plc (the “Company”) Registration Statement on Form F-3 Filed: May 7, 2024 File No. 333-279185 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement to become effective at 4:00 p.m. Eastern Time on May 14, 2024, or as soon thereafter as is practicable, or at such later time as the Company may orally request via telephone call to the staff. The Company hereby authorizes each of Courtney T. Thorne and Eric Blanchard of Cooley LLP to make such request on its behalf. Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Courtney T. Thorne of Cooley LLP at (617) 937-2318, or in her absence, Eric Blanchard of Cooley LLP at (617) 937-2445. Very truly yours, Silence Therapeutics plc By: /s/ Rhonda Hellums Rhonda Hellums Chief Financial Officer